Pharma: Clinic Roundup
Friday, April 27, 2012
Shire plc, of Dublin, Ireland, said its Phase II trial of Vyvanse (lisdexamfetamine dimesylate) for adults with binge-eating disorder met its primary endpoint of significantly reducing the number of binge days per week at the two highest of three doses tested.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.